{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T00:01:01Z","timestamp":1790467261503,"version":"4.1.0"},"reference-count":106,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2023,3,21]],"date-time":"2023-03-21T00:00:00Z","timestamp":1679356800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100002794","name":"Cancerfonden","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002794","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004359","name":"Vetenskapsr\u00e5det","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004359","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004063","name":"Knut och Alice Wallenbergs Stiftelse","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004063","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100007232","name":"Radiumhemmets Forskningsfonder","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100007232","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:p>Genetic diagnostics of hematological malignancies has evolved dramatically over the years, from chromosomal banding analysis to next-generation sequencing, with a corresponding increased capacity to detect clinically relevant prognostic and predictive biomarkers. In diagnostics of patients with chronic lymphocytic leukemia (CLL), we currently apply fluorescence <jats:italic>in situ<\/jats:italic> hybridization (FISH)-based analysis to detect recurrent chromosomal aberrations (del(11q), del(13q), del(17p) and trisomy 12) as well as targeted sequencing (IGHV and <jats:italic>TP53<\/jats:italic> mutational status) for risk-stratifying purposes. These analyses are performed before start of any line of treatment and assist in clinical decision-making including selection of targeted therapy (BTK and BCL2 inhibitors). Here, we present the current view on the genomic landscape of CLL, including an update on recent advances with potential for clinical translation. We discuss different state-of-the-art technologies that are applied to enable precision diagnostics in CLL and highlight important genomic markers with current prognostic and\/or predictive impact as well as those of prospective clinical relevance. In the coming years, it will be important to develop more comprehensive genomic analyses that can capture all types of relevant genetic aberrations, but also to develop highly sensitive assays to detect minor mutations that affect therapy response or confer resistance to targeted therapies. Finally, we will bring up the potential of new technologies and multi-omics analysis to further subclassify the disease and facilitate implementation of precision medicine approaches in this still incurable disease.<\/jats:p>","DOI":"10.3389\/fonc.2023.1146486","type":"journal-article","created":{"date-parts":[[2023,3,21]],"date-time":"2023-03-21T05:07:58Z","timestamp":1679375278000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":19,"title":["Precision diagnostics in chronic lymphocytic leukemia: Past, present and future"],"prefix":"10.3389","volume":"13","author":[{"given":"John","family":"Mollstedt","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Larry","family":"Mansouri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard","family":"Rosenquist","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2023,3,21]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1016\/j.semcancer.2021.05.026","article-title":"Trailblazing precision medicine in Europe: A joint view by genomic medicine Sweden and the centers for personalized medicine, ZPM, in Germany","volume":"84","author":"Stenzinger","year":"2022","journal-title":"Semin Cancer Biol"},{"key":"B2","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/j.semcancer.2020.10.015","article-title":"Next-generation diagnostics for precision oncology: Preanalytical considerations, technical challenges, and available technologies","volume":"84","author":"Walter","year":"2022","journal-title":"Semin Cancer Biol"},{"key":"B3","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1056\/NEJMoa1215637","article-title":"Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia","volume":"369","author":"Byrd","year":"2013","journal-title":"N Engl J Med"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1513257","article-title":"Targeting BCL2 with venetoclax in relapsed chronic lymphocytic leukemia","volume":"374","author":"Roberts","year":"2016","journal-title":"N Engl J Med"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2017-09-806398","article-title":"iwCLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLL","volume":"131","author":"Hallek","year":"2018","journal-title":"Blood"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V46.2.219.219","article-title":"Clinical staging of chronic lymphocytic leukemia","volume":"46","author":"Rai","year":"1975","journal-title":"Blood"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(197708)40:2<855::AID-CNCR2820400239>3.0.CO;2-1","article-title":"A clinical staging system for chronic lymphocytic leukemia: prognostic significance","volume":"40","author":"Binet","year":"1977","journal-title":"Cancer"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1111\/joim.12455","article-title":"Prognostic indices in chronic lymphocytic leukaemia: Where do we stand how do we proceed","volume":"279","author":"Baliakas","year":"2016","journal-title":"J Intern Med"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(80)90622-4","article-title":"Extra chromosome 12 in chronic lymphocytic leukaemia","volume":"1","author":"Gahrton","year":"1980","journal-title":"Lancet"},{"key":"B10","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1111\/j.1601-5223.1988.tb00684.x","article-title":"Chromosome 13\u2013a new marker for b-cell chronic lymphocytic leukemia","volume":"108","author":"Zech","year":"1988","journal-title":"Hereditas"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2018.187583","article-title":"TP53 aberrations in chronic lymphocytic leukemia: An overview of the clinical implications of improved diagnostics","volume":"103","author":"Campo","year":"2018","journal-title":"Haematologica"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2009.27.8762","article-title":"TP53 mutation and survival in chronic lymphocytic leukemia","volume":"28","author":"Zenz","year":"2010","journal-title":"J Clin Oncol"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2018-09-873083","article-title":"Cytogenetic complexity in chronic lymphocytic leukemia: definitions, associations, and clinical impact","volume":"133","author":"Baliakas","year":"2019","journal-title":"Blood"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM200012283432602","article-title":"Genomic aberrations and survival in chronic lymphocytic leukemia","volume":"343","author":"Dohner","year":"2000","journal-title":"N Engl J Med"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0506654102","article-title":"miR-15 and miR-16 induce apoptosis by targeting BCL2","volume":"102","author":"Cimmino","year":"2005","journal-title":"Proc Natl Acad Sci U.S.A."},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2008.274","article-title":"The detection of TP53 mutations in chronic lymphocytic leukemia independently predicts rapid disease progression and is highly correlated with a complex aberrant karyotype","volume":"23","author":"Dicker","year":"2009","journal-title":"Leukemia"},{"key":"B17","doi-asserted-by":"publisher","first-page":"995","DOI":"10.1158\/1078-0432.CCR-08-1630","article-title":"The prognostic value of TP53 mutations in chronic lymphocytic leukemia is independent of Del17p13: implications for overall survival and chemorefractoriness","volume":"15","author":"Rossi","year":"2009","journal-title":"Clin Cancer Res"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2014.196","article-title":"Recurrent mutations refine prognosis in chronic lymphocytic leukemia","volume":"29","author":"Baliakas","year":"2015","journal-title":"Leukemia"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-017-0007-7","article-title":"ERIC recommendations for TP53 mutation analysis in chronic lymphocytic leukemia-update on methodological approaches and results interpretation","volume":"32","author":"Malcikova","year":"2018","journal-title":"Leukemia"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2013.322","article-title":"Feasibility of targeted next-generation sequencing of the TP53 and ATM genes in chronic lymphocytic leukemia","volume":"28","author":"Mansouri","year":"2014","journal-title":"Leukemia"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1097\/HS9.0000000000000707","article-title":"Cytogenetics in chronic lymphocytic leukemia: ERIC perspectives and recommendations","volume":"6","author":"Baliakas","year":"2022","journal-title":"Hemasphere"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V94.6.1848","article-title":"Unmutated ig V(H) genes are associated with a more aggressive form of chronic lymphocytic leukemia","volume":"94","author":"Hamblin","year":"1999","journal-title":"Blood"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V94.6.1840","article-title":"Ig V gene mutation status and CD38 expression as novel prognostic indicators in chronic lymphocytic leukemia","volume":"94","author":"Damle","year":"1999","journal-title":"Blood"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-022-01604-2","article-title":"Immunoglobulin gene sequence analysis in chronic lymphocytic leukemia: the 2022 update of the recommendations by ERIC, the European research initiative on CLL","volume":"36","author":"Agathangelidis","year":"2022","journal-title":"Leukemia"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2014.109777","article-title":"Targeted next-generation sequencing in chronic lymphocytic leukemia: A high-throughput yet tailored approach will facilitate implementation in a clinical setting","volume":"100","author":"Sutton","year":"2015","journal-title":"Haematologica"},{"key":"B26","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1182\/blood-2014-02-556399","article-title":"Development of a comprehensive prognostic index for patients with chronic lymphocytic leukemia","volume":"124","author":"Pflug","year":"2014","journal-title":"Blood"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1038\/nature10113","article-title":"Whole-genome sequencing identifies recurrent mutations in chronic lymphocytic leukaemia","volume":"475","author":"Puente","year":"2011","journal-title":"Nature"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20110921","article-title":"Analysis of the chronic lymphocytic leukemia coding genome: role of NOTCH1 mutational activation","volume":"208","author":"Fabbri","year":"2011","journal-title":"J Exp Med"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1109016","article-title":"SF3B1 and other novel cancer genes in chronic lymphocytic leukemia","volume":"365","author":"Wang","year":"2011","journal-title":"N Engl J Med"},{"key":"B30","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1038\/ng.1032","article-title":"Exome sequencing identifies recurrent mutations of the splicing factor SF3B1 gene in chronic lymphocytic leukemia","volume":"44","author":"Quesada","year":"2012","journal-title":"Nat Genet"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1038\/nature12477","article-title":"Signatures of mutational processes in human cancer","volume":"500","author":"Alexandrov","year":"2013","journal-title":"Nature"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1038\/nature14666","article-title":"Non-coding recurrent mutations in chronic lymphocytic leukaemia","volume":"526","author":"Puente","year":"2015","journal-title":"Nature"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1038\/nature15395","article-title":"Mutations driving CLL and their evolution in progression and relapse","volume":"526","author":"Landau","year":"2015","journal-title":"Nature"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-022-01802-y","article-title":"Different prognostic impact of recurrent gene mutations in chronic lymphocytic leukemia depending on IGHV gene somatic hypermutation status: A study by ERIC in HARMONY","volume":"37","author":"Mansouri","year":"2022","journal-title":"Leukemia"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20142009","article-title":"Functional loss of IkappaBepsilon leads to NF-kappaB deregulation in aggressive chronic lymphocytic leukemia","volume":"212","author":"Mansouri","year":"2015","journal-title":"J Exp Med"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2016.359","article-title":"EGR2 mutations define a new clinically aggressive subgroup of chronic lymphocytic leukemia","volume":"31","author":"Young","year":"2017","journal-title":"Leukemia"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2015-10-674572","article-title":"Whole-exome sequencing in relapsing chronic lymphocytic leukemia: Clinical impact of recurrent RPS15 mutations","volume":"127","author":"Ljungstrom","year":"2016","journal-title":"Blood"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-18-4158","article-title":"The number of signaling pathways altered by driver mutations in chronic lymphocytic leukemia impacts disease outcome","volume":"26","author":"Brieghel","year":"2020","journal-title":"Clin Cancer Res"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2015-05-647578","article-title":"Presence of multiple recurrent mutations confers poor trial outcome of relapsed\/refractory CLL","volume":"126","author":"Guieze","year":"2015","journal-title":"Blood"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-08-373159","article-title":"Mutations of the SF3B1 splicing factor in chronic lymphocytic leukemia: Association with progression and fludarabine-refractoriness","volume":"118","author":"Rossi","year":"2011","journal-title":"Blood"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-03-488197","article-title":"NOTCH1, SF3B1, and TP53 mutations in fludarabine-refractory CLL patients treated with alemtuzumab: Results from the CLL2H trial of the GCLLSG","volume":"122","author":"Schnaiter","year":"2013","journal-title":"Blood"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2013.263","article-title":"SF3B1 mutations correlated to cytogenetics and mutations in NOTCH1, FBXW7, MYD88, XPO1 and TP53 in 1160 untreated CLL patients","volume":"28","author":"Jeromin","year":"2013","journal-title":"Leukemia"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2013.98","article-title":"Distinct patterns of novel gene mutations in poor-prognostic stereotyped subsets of chronic lymphocytic leukemia: The case of SF3B1 and subset 2","volume":"27","author":"Strefford","year":"2013","journal-title":"Leukemia"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2016.141812","article-title":"Different spectra of recurrent gene mutations in subsets of chronic lymphocytic leukemia harboring stereotyped b-cell receptors","volume":"101","author":"Sutton","year":"2016","journal-title":"Haematologica"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-13-0330","article-title":"SF3B1 mutations are associated with alternative splicing in uveal melanoma","volume":"3","author":"Furney","year":"2013","journal-title":"Cancer Discovery"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2014.318","article-title":"The impact of SF3B1 mutations in CLL on the DNA-damage response","volume":"29","author":"Te Raa","year":"2015","journal-title":"Leukemia"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2016.10.005","article-title":"Transcriptomic characterization of SF3B1 mutation reveals its pleiotropic effects in chronic lymphocytic leukemia","volume":"30","author":"Wang","year":"2016","journal-title":"Cancer Cell"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2020.609409","article-title":"The effect of SF3B1 mutation on the DNA damage response and nonsense-mediated mRNA decay in cancer","volume":"10","author":"Leeksma","year":"2020","journal-title":"Front Oncol"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-09-379966","article-title":"Mutations of NOTCH1 are an independent predictor of survival in chronic lymphocytic leukemia","volume":"119","author":"Rossi","year":"2012","journal-title":"Blood"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-10-386144","article-title":"NOTCH1 mutations in CLL associated with trisomy 12","volume":"119","author":"Balatti","year":"2012","journal-title":"Blood"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1038\/377355a0","article-title":"Signalling downstream of activated mammalian notch","volume":"377","author":"Jarriault","year":"1995","journal-title":"Nature"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M400407200","article-title":"Roles for c-myc in self-renewal of hematopoietic stem cells","volume":"279","author":"Satoh","year":"2004","journal-title":"J Biol Chem"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2008-02-139725","article-title":"Constitutively activated notch signaling is involved in survival and apoptosis resistance of b-CLL cells","volume":"113","author":"Rosati","year":"2009","journal-title":"Blood"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-14-0104","article-title":"Acquired initiating mutations in early hematopoietic cells of CLL patients","volume":"4","author":"Damm","year":"2014","journal-title":"Cancer Discovery"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-12-395673","article-title":"Disruption of BIRC3 associates with fludarabine chemorefractoriness in TP53 wild-type chronic lymphocytic leukemia","volume":"119","author":"Rossi","year":"2012","journal-title":"Blood"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2019.219550","article-title":"Biological and clinical implications of BIRC3 mutations in chronic lymphocytic leukemia","volume":"105","author":"Diop","year":"2020","journal-title":"Haematologica"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2019.229161","article-title":"Prognostic and predictive role of gene mutations in chronic lymphocytic leukemia: results from the pivotal phase III study COMPLEMENT1","volume":"105","author":"Tausch","year":"2020","journal-title":"Haematologica"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2017-09-804401","article-title":"Altered patterns of global protein synthesis and translational fidelity in RPS15-mutated chronic lymphocytic leukemia","volume":"132","author":"Bretones","year":"2018","journal-title":"Blood"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2020001717","article-title":"RPS15 mutations rewire RNA translation in chronic lymphocytic leukemia","volume":"5","author":"Ntoufa","year":"2021","journal-title":"Blood Adv"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.1038\/s41588-022-01140-w","article-title":"Molecular map of chronic lymphocytic leukemia and its impact on outcome","volume":"54","author":"Knisbacher","year":"2022","journal-title":"Nat Genet"},{"key":"B61","doi-asserted-by":"publisher","first-page":"544","DOI":"10.1016\/j.jaci.2016.01.018","article-title":"Mutation in IRF2BP2 is responsible for a familial form of common variable immunodeficiency disorder","volume":"138","author":"Keller","year":"2016","journal-title":"J Allergy Clin Immunol"},{"key":"B62","doi-asserted-by":"publisher","first-page":"1001","DOI":"10.1038\/s41419-020-03210-5","article-title":"WDHD1 is essential for the survival of PTEN-inactive triple-negative breast cancer","volume":"11","author":"Ertay","year":"2020","journal-title":"Cell Death Dis"},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.3892\/or.2017.6140","article-title":"Delta-catenin promotes tumorigenesis and metastasis of lung adenocarcinoma","volume":"39","author":"Huang","year":"2018","journal-title":"Oncol Rep"},{"key":"B64","doi-asserted-by":"publisher","DOI":"10.1091\/mbc.e11-04-0364","article-title":"ARHGAP18, a GTPase-activating protein for RhoA, controls cell shape, spreading, and motility","volume":"22","author":"Maeda","year":"2011","journal-title":"Mol Biol Cell"},{"key":"B65","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2012.307","article-title":"NOTCH1 and SF3B1 mutations can be added to the hierarchical prognostic classification in chronic lymphocytic leukemia","volume":"27","author":"Mansouri","year":"2013","journal-title":"Leukemia"},{"key":"B66","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-12-543306","article-title":"Mutations in TLR\/MYD88 pathway identify a subset of young chronic lymphocytic leukemia patients with favorable outcome","volume":"123","author":"Martinez-Trillos","year":"2014","journal-title":"Blood"},{"key":"B67","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2016.134","article-title":"Genomic disruption of the histone methyltransferase SETD2 in chronic lymphocytic leukaemia","volume":"30","author":"Parker","year":"2016","journal-title":"Leukemia"},{"key":"B68","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1186\/s13045-021-01032-2","article-title":"Recurrent XPO1 mutations alter pathogenesis of chronic lymphocytic leukemia","volume":"14","author":"Walker","year":"2021","journal-title":"J Hematol Oncol"},{"key":"B69","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2012-09-458265","article-title":"Integrated mutational and cytogenetic analysis identifies new prognostic subgroups in chronic lymphocytic leukemia","volume":"121","author":"Rossi","year":"2013","journal-title":"Blood"},{"key":"B70","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2018.195032","article-title":"Tailored approaches grounded on immunogenetic features for refined prognostication in chronic lymphocytic leukemia","volume":"104","author":"Baliakas","year":"2019","journal-title":"Haematologica"},{"key":"B71","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2013.01.019","article-title":"Evolution and impact of subclonal mutations in chronic lymphocytic leukemia","volume":"152","author":"Landau","year":"2013","journal-title":"Cell"},{"key":"B72","doi-asserted-by":"publisher","first-page":"2185","DOI":"10.1038\/s41467-017-02329-y","article-title":"The evolutionary landscape of chronic lymphocytic leukemia treated with ibrutinib targeted therapy","volume":"8","author":"Landau","year":"2017","journal-title":"Nat Commun"},{"key":"B73","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-11-539726","article-title":"Clinical impact of small TP53 mutated subclones in chronic lymphocytic leukemia","volume":"123","author":"Rossi","year":"2014","journal-title":"Blood"},{"key":"B74","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2014.297","article-title":"Detailed analysis of therapy-driven clonal evolution of TP53 mutations in chronic lymphocytic leukemia","volume":"29","author":"Malcikova","year":"2015","journal-title":"Leukemia"},{"key":"B75","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2015-07-659144","article-title":"Clinical impact of clonal and subclonal TP53, SF3B1, BIRC3, NOTCH1, and ATM mutations in chronic lymphocytic leukemia","volume":"127","author":"Nadeu","year":"2016","journal-title":"Blood"},{"key":"B76","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2020009530","article-title":"Low-burden TP53 mutations in CLL: clinical impact and clonal evolution within the context of different treatment options","volume":"138","author":"Malcikova","year":"2021","journal-title":"Blood"},{"key":"B77","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1400029","article-title":"Resistance mechanisms for the bruton's tyrosine kinase inhibitor ibrutinib","volume":"370","author":"Woyach","year":"2014","journal-title":"N Engl J Med"},{"key":"B78","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-06-719294","article-title":"Clonal evolution leading to ibrutinib resistance in chronic lymphocytic leukemia","volume":"129","author":"Ahn","year":"2017","journal-title":"Blood"},{"key":"B79","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2016.70.2282","article-title":"BTK(C481S)-mediated resistance to ibrutinib in chronic lymphocytic leukemia","volume":"35","author":"Woyach","year":"2017","journal-title":"J Clin Oncol"},{"key":"B80","doi-asserted-by":"publisher","first-page":"11589","DOI":"10.1038\/ncomms11589","article-title":"Clonal evolution in patients with chronic lymphocytic leukaemia developing resistance to BTK inhibition","volume":"7","author":"Burger","year":"2016","journal-title":"Nat Commun"},{"key":"B81","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-18-1119","article-title":"Acquisition of the recurrent Gly101Val mutation in BCL2 confers resistance to venetoclax in patients with progressive chronic lymphocytic leukemia","volume":"9","author":"Blombery","year":"2019","journal-title":"Cancer Discovery"},{"key":"B82","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.777587","article-title":"Notch2 increases the resistance to venetoclax-induced apoptosis in chronic lymphocytic leukemia b cells by inducing mcl-1","volume":"11","author":"Fiorcari","year":"2021","journal-title":"Front Oncol"},{"key":"B83","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1111\/bjh.12539","article-title":"Targeted resequencing for analysis of clonal composition of recurrent gene mutations in chronic lymphocytic leukaemia","volume":"163","author":"Jethwa","year":"2013","journal-title":"Br J Haematol"},{"key":"B84","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2019.234716","article-title":"Comparative analysis of targeted next-generation sequencing panels for the detection of gene mutations in chronic lymphocytic leukemia: an ERIC multi-center study","volume":"106","author":"Sutton","year":"2021","journal-title":"Haematologica"},{"key":"B85","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2020004056","article-title":"Validation of the EuroClonality-NGS DNA capture panel as an integrated genomic tool for lymphoproliferative disorders","volume":"5","author":"Stewart","year":"2021","journal-title":"Blood Adv"},{"key":"B86","doi-asserted-by":"publisher","DOI":"10.1016\/j.jmoldx.2021.05.007","article-title":"LYmphoid NeXt-generation sequencing (LYNX) panel: A comprehensive capture-based sequencing tool for the analysis of prognostic and predictive markers in lymphoid malignancies","volume":"23","author":"Navrkalova","year":"2021","journal-title":"J Mol Diagn"},{"key":"B87","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/j.annonc.2020.09.019","article-title":"Chronic lymphocytic leukaemia: ESMO clinical practice guidelines for diagnosis, treatment and follow-up","volume":"32","author":"Eichhorst","year":"2021","journal-title":"Ann Oncol"},{"key":"B88","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-019-0602-x","article-title":"Long-term efficacy and safety of first-line ibrutinib treatment for patients with CLL\/SLL: 5 years of follow-up from the phase 3 RESONATE-2 study","volume":"34","author":"Burger","year":"2020","journal-title":"Leukemia"},{"key":"B89","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2019004492","article-title":"Prognostic and predictive impact of genetic markers in patients with CLL treated with obinutuzumab and venetoclax","volume":"135","author":"Tausch","year":"2020","journal-title":"Blood"},{"key":"B90","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2021006434","article-title":"Up to 8-year follow-up from RESONATE-2: first-line ibrutinib treatment for patients with chronic lymphocytic leukemia","volume":"6","author":"Barr","year":"2022","journal-title":"Blood Adv"},{"key":"B91","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2021014488","article-title":"Fixed-duration ibrutinib plus venetoclax for first-line treatment of CLL: primary analysis of the CAPTIVATE FD cohort","volume":"139","author":"Tam","year":"2022","journal-title":"Blood"},{"key":"B92","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-020-0923-9","article-title":"Immunoglobulin gene analysis in chronic lymphocytic leukemia in the era of next generation sequencing","volume":"34","author":"Davi","year":"2020","journal-title":"Leukemia"},{"key":"B93","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2016.322","article-title":"Antigen receptor stereotypy in chronic lymphocytic leukemia","volume":"31","author":"Stamatopoulos","year":"2017","journal-title":"Leukemia"},{"key":"B94","doi-asserted-by":"publisher","DOI":"10.1038\/s41588-022-01211-y","article-title":"Whole-genome sequencing of chronic lymphocytic leukemia identifies subgroups with distinct biological and clinical features","volume":"54","author":"Robbe","year":"2022","journal-title":"Nat Genet"},{"key":"B95","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2024534","article-title":"Genome sequencing as an alternative to cytogenetic analysis in myeloid cancers","volume":"384","author":"Duncavage","year":"2021","journal-title":"N Engl J Med"},{"key":"B96","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2022.842507","article-title":"A study protocol for validation and implementation of whole-genome and -transcriptome sequencing as a comprehensive precision diagnostic test in acute leukemias","volume":"9","author":"Berglund","year":"2022","journal-title":"Front Med (Lausanne)"},{"key":"B97","doi-asserted-by":"publisher","first-page":"3390","DOI":"10.1038\/s41467-020-17095-7","article-title":"IgCaller for reconstructing immunoglobulin gene rearrangements and oncogenic translocations from whole-genome sequencing in lymphoid neoplasms","volume":"11","author":"Nadeu","year":"2020","journal-title":"Nat Commun"},{"key":"B98","doi-asserted-by":"publisher","DOI":"10.1038\/ng.3488","article-title":"DNA Methylation dynamics during b cell maturation underlie a continuum of disease phenotypes in chronic lymphocytic leukemia","volume":"48","author":"Oakes","year":"2016","journal-title":"Nat Genet"},{"key":"B99","doi-asserted-by":"publisher","first-page":"598","DOI":"10.1038\/leu.2014.252","article-title":"A b-cell epigenetic signature defines three biologic subgroups of chronic lymphocytic leukemia with clinical impact","volume":"29","author":"Queir\u00f3s","year":"2015","journal-title":"Leukemia"},{"key":"B100","doi-asserted-by":"publisher","DOI":"10.1038\/ng.2894","article-title":"Identification of functional cooperative mutations of SETD2 in human acute leukemia","volume":"46","author":"Zhu","year":"2014","journal-title":"Nat Genet"},{"key":"B101","doi-asserted-by":"publisher","first-page":"6226","DOI":"10.1038\/s41467-022-33385-8","article-title":"Proteogenomics refines the molecular classification of chronic lymphocytic leukemia","volume":"13","author":"Herbst","year":"2022","journal-title":"Nat Commun"},{"key":"B102","doi-asserted-by":"publisher","DOI":"10.15252\/msb.20178124","article-title":"Multi-omics factor analysis-a framework for unsupervised integration of multi-omics data sets","volume":"14","author":"Argelaguet","year":"2018","journal-title":"Mol Syst Biol"},{"key":"B103","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1038\/s41408-022-00690-w","article-title":"B cell receptor signaling drives APOBEC3 expression via direct enhancer regulation in chronic lymphocytic leukemia b cells","volume":"12","author":"Wang","year":"2022","journal-title":"Blood Cancer J"},{"key":"B104","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-022-01927-8","article-title":"Detection of early seeding of Richter transformation in chronic lymphocytic leukemia","volume":"28","author":"Nadeu","year":"2022","journal-title":"Nat Med"},{"key":"B105","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2022016040","article-title":"Single-cell multiomics reveal the scale of multilayered adaptations enabling CLL relapse during venetoclax therapy","volume":"140","author":"Thijssen","year":"2022","journal-title":"Blood"},{"key":"B106","doi-asserted-by":"publisher","DOI":"10.1038\/s43018-022-00332-x","article-title":"The molecular tumor board portal supports clinical decisions and automated reporting for precision oncology","volume":"3","author":"Tamborero","year":"2022","journal-title":"Nat Cancer"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2023.1146486\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,3,24]],"date-time":"2023-03-24T12:15:40Z","timestamp":1679660140000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2023.1146486\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3,21]]},"references-count":106,"alternative-id":["10.3389\/fonc.2023.1146486"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2023.1146486","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,3,21]]},"article-number":"1146486"}}